The HSV-2 vaccine candidate, GEN-003, generated highly significant reductions in clinical lesion days and rate of viral shedding at six months after the final vaccine dose. The study showed a 72% reduction in lesion days and a 50% reduction in mean viral shedding from baseline.
In the Phase 2b trial, TC-5214 outperformed placebo in treating major depressive disorder, achieving high statistical significance on all secondary outcome measures. The study demonstrated a favorable tolerability profile and potential as an augmentation treatment for SSRI-resistant depression.
Locteron showed a significant reduction in flu-like symptoms compared to PEG-Intron, with patients experiencing an 80% lower severity score. The trial demonstrated comparable anti-viral effects and tolerability with the controlled-release interferon alpha.
Researchers used a six-gene model to stratify patients with castration-resistant prostate cancer, predicting survival and accuracy rates. The study found the model accurate in predicting low-risk patients' survival and high-risk patients' mortality.
A Phase 2 clinical trial of GCS-100, a polysaccharide targeting galectin-3, demonstrates apoptosis induction and reduced leukocyte counts in relapsed CLL patients. The treatment was generally well tolerated with mild-to-moderate adverse events.
The study presents positive interim results of using ALDESORT to isolate cord blood stem cells, showing improved overall survival at 90.9% compared to a historical control group. The infusion of cells enriched with ALDESORT appears to improve the speed and efficacy of cord blood transplantations.
The LEX System demonstrated the ability to produce monoclonal antibodies with homogeneous glycosylation structures, reducing production risks and costs. The system's success was shown through enhanced affinity for Fc receptors and increased effector function in oncology and autoimmune indications.